This is Cipla’s second launch within the diagnostics area after Elifast ELISA Test Kit. In this collaboration, Cipla will likely be liable for the advertising and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will likely be manufactured by Premier Medical Corporation Private Limited.
The take a look at is a speedy point-of-care nasopharyngeal swab take a look at that instantly detects the presence or absence of coronavirus antigen within the affected person’s physique, producing outcomes inside 15-20 minutes. Only authorised labs are permitted by ICMR to conduct the speedy antigen testing. The take a look at will likely be marketed beneath the model title ‘CIPtest’.
CIPtest is a dependable high-performing equipment that has been validated and authorised by ICMR. It is discovered to have specificity and sensitivity of 98.09 per cent and upto 75 per cent respectively. The take a look at just isn’t solely speedy with a fast turn-around time, but additionally permits straightforward interpretation of outcomes with out the necessity of any extra instrument. Cipla’s expansive distribution community will assist in making certain provide of kits throughout the nation.